QUOIN PHARMACEUTICALS LTD DRC

NASDAQ: QNRX (Quoin Pharmaceuticals, Ltd.)

最近更新时间: 15 May, 11:03AM

6.87

-0.78 (-10.20%)

前收盘价格 7.65
收盘价格 7.16
成交量 126,371
平均成交量 (3个月) 367,532
市值 4,040,707
股市价格/股市净资产 (P/B) 0.390
52周波幅
5.01 (-27%) — 54.95 (699%)
利润日期 6 Aug 2025 - 11 Aug 2025
稀释每股收益 (EPS TTM) -66.85
总债务/股东权益 (D/E MRQ) 31.76%
流动比率 (MRQ) 3.57
营业现金流 (OCF TTM) -7.86 M
杠杆自由现金流 (LFCF TTM) -4.28 M
资产报酬率 (ROA TTM) -42.72%
股东权益报酬率 (ROE TTM) -120.55%

市场趋势

短期 中期
行业 Biotechnology (US) 看跌 看跌
Biotechnology (全球的) 看跌 看跌
股票 Quoin Pharmaceuticals, Ltd. 混合的 混合的

AIStockmoo 评分

0.4
分析师共识 -2.0
内部交易活动 NA
价格波动 0.5
技术平均移动指标 1.0
技术振荡指标 2.0
平均 0.38

相关股票

股票 市值 DY P/E(TTM) P/B
QNRX 4 M - - 0.390
MTSR 3 B - - -
PROK 2 B - - 97.15
GYRE 819 M - 453.50 13.50
MAZE 530 M - 172.86 1.50
SEPN 412 M - - 1.08

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

部门 Healthcare
行业 Biotechnology
内部持股比例 7.08%
机构持股比例 7.60%

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
22 May 2025 公告 Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
20 May 2025 公告 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
14 May 2025 公告 Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
13 May 2025 公告 Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
06 May 2025 公告 Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
30 Apr 2025 公告 Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
10 Apr 2025 公告 Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
02 Apr 2025 公告 Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
25 Mar 2025 公告 Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
06 Mar 2025 公告 Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
04 Mar 2025 公告 Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票